Release Date: June 8, 2012
National Human Genome Research Institute (NHGRI)
National Institute on Drug Abuse (NIDA)
The purpose of this Notice is to inform applicants that applications submitted in response to RFA-HG-12-009 for Clinical Sequencing Exploratory Research will NOT use the U01 Activity Code but instead will use UM1 Activity Code for Multi-Component Research Project Cooperative Agreements. This change in activity code will require applicants responding to this FOA to use the PHS 398 instructions and forms for paper submission.
Applicants should replace Section IV. Application and Submission Information parts 1 and 2 in RFA-HG-12-009 with the following:
Part 2. Section IV. Application and Submission Information
1. Address to Request Application Package
Applicants are required to prepare applications according to the current PHS 398 application forms in accordance with the PHS 398 Application Guide.
2. Content and Form of Application Submission
It is critical that applicants follow the instructions in the PHS398 Application Guide, except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Letter of Intent
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
Descriptive title of proposed research
Name, address, and telephone number of the PD(s)/PI(s)
Names of other key personnel
Participating institutions
Number and title of this funding opportunity
The letter of intent should be sent to:
Bradley A. Ozenberger, Ph.D.
Program Director
National Human Genome Research Institute
5635 Fishers Lane
Suite 4076, MSC 9305
Bethesda, MD 20892
Telephone: 301-496-7531
Email: bozenberger@mail.nih.gov
Application Submission
Applications must be prepared using the PHS 398 research grant application forms and instructions for preparing a research grant application. Submit a signed, typewritten original of the application, including the checklist, and three signed photocopies in one package to:
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710 (U.S. Postal Service Express or regular mail)
Bethesda, MD 20817 (for express/courier service; non-USPS service)
At the time of submission, two additional paper copies of the application and all copies of the appendix files must be sent to:
Ken Nakamura, Ph.D.
Scientific Review Branch
National Human Genome Research Institute
5635 Fishers Lane
Suite 4076, MSC 9305
Bethesda, MD 20892
Telephone: (301) 496-7531
Email: pozzatr@mail.nih.gov
Page Limitations
All page limitations described in the PHS398 Application Guide must be followed, with the following exceptions or additional requirements:
Applications to this FOA should include separate research plans for three projects: 1) Clinical Genomic Study (12 pages); 2) Sequencing, Analysis and Interpretation of Sequencing Data (12 pages); 3) Ethical and Psychosocial Implications Research (12 pages); plus a Project Management Plan (6 pages). Budget pages should be submitted as a composite describing support for all components.
All other aspects of the FOA remain unchanged, including the terms and conditions of the cooperative agreement.
Please direct all inquiries to:
Bradley A. Ozenberger, Ph.D.
Program Director
National Human Genome Research Institute
5635 Fishers Lane
Suite 4076, MSC 9305
Bethesda, MD 20892
Telephone: 301-496-7531
Email: bozenberger@mail.nih.gov
and Human Services (HHS)
